Pituitary adenoma comprises 10%‐15% of all diagnosed intracranial tumours.1 PRLoma is the most common type of functional pituitary adenoma, with a prevalence of 100 per 1 million people.2 Currently, dopamine agonists such as BC are the primary therapy for PRLoma, with a high probability of controlling tumour size and reducing PRL level. This evidence concerns the gene PRL and pituitary gland adenoma.